- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: DPD deficiency.
Displaying page 1 of 1.
EudraCT Number: 2006-002861-37 | Sponsor Protocol Number: EURABEL-2 | Start Date*: 2007-01-19 |
Sponsor Name:Ziekenhuisapotheek Meppel-Hoogeveen | ||
Full Title: Evaluation of the oral uracil loading test as a sensitive, simple and cheap method to detect DPD deficiency. | ||
Medical condition: Extreme toxicity during of after chemotherapy with a 5-fluorouracil of capecitabine containing regimen for colorectal, breast or head and neck cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002037-31 | Sponsor Protocol Number: 2017/15 | Start Date*: 2020-01-07 | |||||||||||
Sponsor Name:Centre Antoine-LACASSAGNE | |||||||||||||
Full Title: Study of the impact of DPD activity on the efficacy of capecitabine | |||||||||||||
Medical condition: Metastatic HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005064-15 | Sponsor Protocol Number: M14DPD | Start Date*: 2015-02-12 |
Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV) | ||
Full Title: Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines | ||
Medical condition: Types of cancer for which capecitabine and 5-fluorouracil are authorized, this includes colorectal cancer, gastric cancer and locally advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006144-18 | Sponsor Protocol Number: FIRE-9/PORT | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the eff... | |||||||||||||
Medical condition: Metastatic colorectal cancer after definite interventional therapy of all lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002727-11 | Sponsor Protocol Number: CRO-2020-043 | Start Date*: 2023-08-02 | |||||||||||||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO | |||||||||||||||||||||||
Full Title: Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study. | |||||||||||||||||||||||
Medical condition: Patients with locally advanced, potentially resectable, Middle-Distal Rectal Carcinoma, stage T3c-d N1-2, MRF + or T4N0-2, EMVI - / + (High-Risk) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002095-40 | Sponsor Protocol Number: HM-RE-2017-01 | Start Date*: 2019-02-04 | |||||||||||
Sponsor Name:Fundación de investigación de HM Hospitales | |||||||||||||
Full Title: Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with recta... | |||||||||||||
Medical condition: Rectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004366-18 | Sponsor Protocol Number: MAZEPPA_D19-02 | Start Date*: 2020-03-03 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: MAZEPPA: Phase II PRODIGE-GERCOR study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreat... | |||||||||||||
Medical condition: Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007974-39 | Sponsor Protocol Number: AIO-KRK-0207 | Start Date*: 2009-08-04 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyr... | ||||||||||||||||||
Medical condition: Histologically confirmed and inoperable or irresectable metastatic colorectal cancer (stage IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000273-81 | Sponsor Protocol Number: UC-GIG-2203 | Start Date*: 2022-09-13 | |||||||||||||||||||||
Sponsor Name:UNICANCER | |||||||||||||||||||||||
Full Title: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurre... | |||||||||||||||||||||||
Medical condition: Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003858-33 | Sponsor Protocol Number: AM0010-301 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi... | |||||||||||||
Medical condition: Advanced Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000096-32 | Sponsor Protocol Number: METRO-PD1-1708 | Start Date*: 2018-11-15 | ||||||||||||||||||||||||||
Sponsor Name:Centre Oscar Lambret | ||||||||||||||||||||||||||||
Full Title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma | ||||||||||||||||||||||||||||
Medical condition: Progressive or refractory : • high grade glioma • neuroblastoma • other cerebral tumors • lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
